| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Michel Goedert, R Anthony Crowther, Sjors H W Scheres, Maria Grazia Spillantin. Tau and neurodegeneration. Cytoskeleton (Hoboken, N.J.). 2023-12-14. PMID:38073060. |
first identified in 1975, tau was implicated in alzheimer's disease 10 years later. |
2023-12-14 |
2023-12-17 |
human |
| Christopher E Ramsden, Daisy Zamora, Mark S Horowitz, Jahandar Jahanipour, Elizabeth Calzada, Xiufeng Li, Gregory S Keyes, Helen C Murray, Maurice A Curtis, Richard M Faull, Andrea Sedlock, Dragan Mari. ApoER2-Dab1 disruption as the origin of pTau-associated neurodegeneration in sporadic Alzheimer's disease. Acta neuropathologica communications. vol 11. issue 1. 2023-12-14. PMID:38093390. |
in sporadic alzheimer's disease (sad) specific regions, layers and neurons accumulate hyperphosphorylated tau (ptau) and degenerate early while others remain unaffected even in advanced disease. |
2023-12-14 |
2023-12-17 |
Not clear |
| Ling Lei, Yong Luo, Dongkun Kang, Fumin Yang, Dongli Meng, Jian-Zhi Wang, Rong Liu, Xiaochuan Wang, Hong-Lian L. Gypenoside IX restores Akt/GSK-3β pathway and alleviates Alzheimer's disease-like neuropathology and cognitive deficits. Aging. vol 15. 2023-12-14. PMID:38095632. |
the main pathological changes of alzheimer's disease (ad), a progressive neurodegenerative disorder, include senile plaque (deposited by amyloid beta), neurofibrillary tangle (formed by paired helical filaments composed of hyperphosphorylated tau), and massive loss of neurons. |
2023-12-14 |
2023-12-17 |
rat |
| Joseph Giorgio, Jenna N Adams, Anne Maass, William J Jagust, Michael Breakspea. Amyloid induced hyperexcitability in default mode network drives medial temporal hyperactivity and early tau accumulation. Neuron. 2023-12-14. PMID:38096815. |
in early alzheimer's disease (ad) β-amyloid (aβ) deposits throughout association cortex and tau appears in the entorhinal cortex (ec). |
2023-12-14 |
2023-12-17 |
Not clear |
| Neelam Younas, Tayyaba Saleem, Abrar Younas, Inga Zer. Nuclear face of Tau: an inside player in neurodegeneration. Acta neuropathologica communications. vol 11. issue 1. 2023-12-13. PMID:38087392. |
tau (tubulin associated unit) protein is a major hallmark of alzheimer's disease (ad) and tauopathies. |
2023-12-13 |
2023-12-17 |
human |
| Neelam Younas, Tayyaba Saleem, Abrar Younas, Inga Zer. Nuclear face of Tau: an inside player in neurodegeneration. Acta neuropathologica communications. vol 11. issue 1. 2023-12-13. PMID:38087392. |
in this review, we explore the nuclear face of tau protein, its nuclear localizations and functions and its linkage with alzheimer's disease. |
2023-12-13 |
2023-12-17 |
human |
| David Vicente-Zurdo, Noelia Rosales-Conrado, María Eugenia León-Gonzále. Unravelling the in vitro and in vivo potential of selenium nanoparticles in Alzheimer's disease: A bioanalytical review. Talanta. vol 269. 2023-12-12. PMID:38086100. |
alzheimer's disease (ad) is a devastating neurodegenerative disorder characterized by progressive cognitive decline and the accumulation of beta-amyloid plaques and tau tangles in the brain. |
2023-12-12 |
2023-12-17 |
mouse |
| Dina Rodrigues Martins, Fern Sha, Wim Van der Elst, Pei-Yu Shih, Jens Devoght, Kristof Van Kolen, Marc Mercken, Bianca Van Broeck, Paul Declerck, Clara Theuni. Anti-tau intrabodies: From anti-tau immunoglobulins to the development of functional scFv intrabodies. Molecular therapy. Methods & clinical development. vol 31. 2023-12-11. PMID:38074413. |
in the context of intracellular protein misfolding and aggregation, such as tau pathology in alzheimer's disease, intrabodies have become an interesting approach as there is the possibility to target early stages of aggregation. |
2023-12-11 |
2023-12-17 |
mouse |
| Tabea M Soelter, Timothy C Howton, Amanda D Clark, Vishal H Oza, Brittany N Lasseign. Altered Glia-Neuron Communication in Alzheimer's Disease Affects WNT, p53, and NFkB Signaling Determined by snRNA-seq. bioRxiv : the preprint server for biology. 2023-12-11. PMID:38076822. |
alzheimer's disease is the most common cause of dementia and is characterized by amyloid-β plaques, tau neurofibrillary tangles, and neuronal loss. |
2023-12-11 |
2023-12-17 |
Not clear |
| Kaitlyn M Dybing, Cecelia J Vetter, Desarae A Dempsey, Soumilee Chaudhuri, Andrew J Saykin, Shannon L Risache. Traumatic brain injury and Alzheimer's Disease biomarkers: A systematic review of findings from amyloid and tau positron emission tomography (PET). medRxiv : the preprint server for health sciences. 2023-12-11. PMID:38077068. |
traumatic brain injury and alzheimer's disease biomarkers: a systematic review of findings from amyloid and tau positron emission tomography (pet). |
2023-12-11 |
2023-12-17 |
human |
| Vanshika Doshi, Garima Joshi, Sanjay Sharma, Deepak Choudhar. Gene therapy: an alternative to treat Alzheimer's disease. Naunyn-Schmiedeberg's archives of pharmacology. 2023-12-11. PMID:38078920. |
various hypotheses that may contribute to alzheimer's disease have been found during decades of survey, including tau theory, the amyloid theory, the cholinergic hypothesis, and the oxidative stress hypothesis. |
2023-12-11 |
2023-12-17 |
Not clear |
| Victor Hugo Bustos, Yashoda Krishna Sunkari, Anjana Sinha, Maria Pulina, Ashley Bispo, Maya Hopkins, Alison Lam, Sydney F Kriegsman, Emily Mui, Emily Chang, Ana Jedlicki, Hannah Rosenthal, Marc Flajolet, Subhash C Sinh. Rational Development of a Small-Molecule Activator of CK1γ2 That Decreases C99 and Beta-Amyloid Levels. ACS chemical biology. 2023-12-11. PMID:38079390. |
alzheimer's disease (ad) is a debilitating neurodegenerative disorder characterized by the accumulation of β-amyloid (aβ), c99, and tau in vulnerable areas of the brain. |
2023-12-11 |
2023-12-17 |
Not clear |
| Michael S LaCroix, Efrosini Artikis, Brian D Hitt, Joshua D Beaver, Sandi-Jo Estill-Terpack, Kelly Gleason, Carol A Tamminga, Bret M Evers, Charles L White, Byron Caughey, Marc I Diamon. Tau seeding without tauopathy. The Journal of biological chemistry. 2023-12-10. PMID:38072056. |
neurodegenerative tauopathies such as alzheimer's disease (ad) are caused by brain accumulation of tau assemblies. |
2023-12-10 |
2023-12-17 |
mouse |
| Ece Guler, Humeyra Betul Yekeler, Gita Parviz, Saliha Aydin, Asima Asghar, Murat Dogan, Fakhera Ikram, Deepak M Kalaskar, Muhammet Emin Ca. Vitamin B International journal of biological macromolecules. 2023-12-08. PMID:38065445. |
vitamin b alzheimer's disease (ad) is a neurodegeneration type that is biologically recognizable via β-amyloid plaques and tau neurofibril tangles. |
2023-12-08 |
2023-12-17 |
Not clear |
| Shannon Zhuang, Pijush Chakraborty, Markus Zweckstette. Regulation of tau by peptidyl-prolyl isomerases. Current opinion in structural biology. vol 84. 2023-12-07. PMID:38061261. |
therefore, the ability of ppiases to structurally modify and regulate tau should be further investigated due to its potential therapeutic implications for alzheimer's disease and other tauopathies. |
2023-12-07 |
2023-12-17 |
Not clear |
| Wenlu Li, Steffen Tiedt, Eng H L. Tau in the pancreas: understanding the link between type 2 diabetes mellitus and Alzheimer's disease. Signal transduction and targeted therapy. vol 8. issue 1. 2023-12-06. PMID:38057303. |
tau in the pancreas: understanding the link between type 2 diabetes mellitus and alzheimer's disease. |
2023-12-06 |
2023-12-10 |
Not clear |
| Jie Lay Lim, Chin-Jung Lin, Chih-Ching Huang, Lin-Chau Chan. Curcumin-derived carbon quantum dots: Dual actions in mitigating tau hyperphosphorylation and amyloid beta aggregation. Colloids and surfaces. B, Biointerfaces. vol 234. 2023-12-06. PMID:38056413. |
the amyloid cascade and tau hypotheses both hold significant implications for the pathogenesis of alzheimer's disease (ad). |
2023-12-06 |
2023-12-10 |
Not clear |
| Kerry T Sun, Tark Patel, Sang-Gyun Kang, Allan Yarahmady, Mahalashmi Srinivasan, Olivier Julien, Jónathan Heras, Sue-Ann Mo. Disease-Associated Mutations in Tau Encode for Changes in Aggregate Structure Conformation. ACS chemical neuroscience. 2023-12-06. PMID:38054595. |
cryo-em studies have shown that the packed fibril core of tau adopts distinct structures in different tauopathies, such as alzheimer's disease, corticobasal degeneration, and progressive supranuclear palsy. |
2023-12-06 |
2023-12-10 |
Not clear |
| . Expression of Concern: Identification of the Sites of Tau Hyperphosphorylation and Activation of Tau Kinases in Synucleinopathies and Alzheimer's Diseases. PloS one. vol 18. issue 12. 2023-12-05. PMID:38051714. |
expression of concern: identification of the sites of tau hyperphosphorylation and activation of tau kinases in synucleinopathies and alzheimer's diseases. |
2023-12-05 |
2023-12-10 |
Not clear |
| Jinwang Ye, Huali Wan, Sihua Chen, Gong-Ping Li. Targeting tau in Alzheimer's disease: from mechanisms to clinical therapy. Neural regeneration research. vol 19. issue 7. 2023-12-05. PMID:38051891. |
targeting tau in alzheimer's disease: from mechanisms to clinical therapy. |
2023-12-05 |
2023-12-10 |
Not clear |